Photocure ASA - New CFO Appointed

Oslo, Norway, October 22, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer
Company, is today announcing that Dennis Camporeale has been appointed as Chief
Financial Officer, effective on Monday, October 26, 2026.

Dennis Camporeale brings 25 years of experience as senior healthcare investment
banker and corporate finance leader across life science tools, diagnostics,
medtech and broader healthcare. He most recently led the Life Science Tools and
Diagnostics practice at Canaccord Genuity, advising boards and executive teams
on capital raising, M&A, restructuring and strategic development. Alongside his
advisory background, Mr. Camporeale brings meaningful operational experience
from Ally Financial, where he helped transform GMAC from a captive finance
subsidiary into a standalone public company. He supported the company's
successful US IPO, international divestments and the development of the
financial controls, governance structures and reporting processes required for a
publicly listed organisation.

"I am delighted to welcome Dennis to Photocure as our new CFO. His experience
across medtech, diagnostics and broader life sciences investment banking brings
a valuable combination of industry insight, financial expertise and strategic
perspective to the company," said Dan Schneider, CEO of Photocure. "As we
continue to advance our growth strategy and broaden our reach to unlock the full
potential of our emerging portfolio, Dennis's experience will be instrumental in
helping us execute our ambitions and create long-term value for patients,
partners and shareholders."

For more information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II -
Issuer Rules.
of the Norwegian Securities Trading Act and Euronext Oslo Rule Book II -\
Issuer Rules.\